康方生物：持续深耕肿瘤治疗领域

经济参考网11-28

康方生物(09926.HK)创始人、董事长夏瑜在11月25日举行的“2025第十七届中国医药企业家科学家投资家大会中国医药创新趋势论坛”上表示，公司将持续深耕肿瘤治疗领域，同时拓展多疾病赛道，让中国创新药惠及更多患者。随着全球研发资源的持续投入和技术路径的不断革新，肿瘤免疫治疗将继续引领生物医药产业的发展方向。在这一关键赛道上，中国创新力量表现突出。夏瑜称，康方生物将肿瘤免疫治疗的发展划分为两个...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2587759313?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-28 22:12","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2587759313","market":"hk","top_or_hot":-1,"title":"康方生物：持续深耕肿瘤治疗领域","media":"经济参考网","content":"<div>\n<p>康方生物(09926.HK)创始人、董事长夏瑜在11月25日举行的“2025第十七届中国医药企业家科学家投资家大会中国医药创新趋势论坛”上表示，公司将持续深耕肿瘤治疗领域，同时拓展多疾病赛道，让中国创新药惠及更多患者。随着全球研发资源的持续投入和技术路径的不断革新，肿瘤免疫治疗将继续引领生物医药产业的发展方向。在这一关键赛道上，中国创新力量表现突出。夏瑜称，康方生物将肿瘤免疫治疗的发展划分为两个...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511282214139784f728&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>康方生物：持续深耕肿瘤治疗领域</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n康方生物：持续深耕肿瘤治疗领域\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-28 22:12 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511282214139784f728&s=b><strong>经济参考网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>康方生物(09926.HK)创始人、董事长夏瑜在11月25日举行的“2025第十七届中国医药企业家科学家投资家大会中国医药创新趋势论坛”上表示，公司将持续深耕肿瘤治疗领域，同时拓展多疾病赛道，让中国创新药惠及更多患者。随着全球研发资源的持续投入和技术路径的不断革新，肿瘤免疫治疗将继续引领生物医药产业的发展方向。在这一关键赛道上，中国创新力量表现突出。夏瑜称，康方生物将肿瘤免疫治疗的发展划分为两个...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511282214139784f728&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1720050803.USD","symbol_name":"安联全方位中国股票基金","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511282214139784f728&s=b","article_id":"2587759313","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511282214139784f728&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2587759313","pubTimestamp":1764339123,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"康方生物创始人、董事长夏瑜在11月25日举行的“2025第十七届中国医药企业家科学家投资家大会中国医药创新趋势论坛”上表示，公司将持续深耕肿瘤治疗领域，同时拓展多疾病赛道，让中国创新药惠及更多患者。随着全球研发资源的持续投入和技术路径的不断革新，肿瘤免疫治疗将继续引领生物医药产业的发展方向。夏瑜称，康方生物将肿瘤免疫治疗的发展划分为两个清晰的阶段。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1720050803.USD":"安联全方位中国股票基金","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0634319403.HKD":"ALLIANZ HONG KONG EQUITY \"AT\" (HKD) ACC","LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0737861772.HKD":"FIDELITY EMERGING ASIA \"A \" (HKD) ACC","09926":"康方生物","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","LU0348783233.USD":"安联东方收入型 CI A Dis美元","LU2476274308.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (USD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0348784397.USD":"ALLIANZ ORIENTAL INCOME \"A\" (USD) ACC","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2778985437.USD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"A\" (USD) INC","BK1574":"生物医药B类股","LU2476274720.SGD":"ALLIANZ CHINA FUTURE TECHNOLOGIES \"AT\" (SGDHDG) ACC","LU0561508036.HKD":"ALLIANZ CHINA EQUITY \"A\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0348766576.USD":"ALLIANZ LITTLE DRAGONS \"A\" (USD) INC","BK1583":"高瓴概念","LU0348767384.USD":"ALLIANZLITTLE DRAGONS \"A\" (USD) ACC","LU2399975544.HKD":"ALLIANZ ALL CHINA EQUITY \"AT\" (HKD) ACC","LU0417516571.SGD":"Allianz Oriental Income Cl AT Acc SGD","06078":"海吉亚医疗","BK1209":"保健护理机构","LU0348827113.USD":"ALLIANZ RCM CHINA \"AT\" ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU0329678170.USD":"FIDELITY EMERGING ASIA \"A\" (USD) INC","LU0329678337.USD":"FIDELITY EMERGING ASIA \"A\" (USD)","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC"},"translate_title":"Akeso Bio: Continue to deepen the field of tumor treatment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1.5,"06078":1.5},"content_text":"康方生物(09926.HK)创始人、董事长夏瑜在11月25日举行的“2025第十七届中国医药企业家科学家投资家大会中国医药创新趋势论坛”上表示，公司将持续深耕肿瘤治疗领域，同时拓展多疾病赛道，让中国创新药惠及更多患者。随着全球研发资源的持续投入和技术路径的不断革新，肿瘤免疫治疗将继续引领生物医药产业的发展方向。在这一关键赛道上，中国创新力量表现突出。夏瑜称，康方生物将肿瘤免疫治疗的发展划分为两个清晰的阶段。以PD-1单抗为代表的1.0时代，如O药和K药，在多种肿瘤治疗中取得突破，成为标准疗法，尤其是在肺癌领域战胜化疗，标志着免疫治疗正式成为主流，但免疫检查点抑制剂在不同瘤种和适应症人群中的疗效差异巨大，1.0时代因此面临巨大的临床困境：免疫联合疗法难以再进一步突破局限。发展到2.0时代，IO双抗成为下一代联合疗法的基石，开启了肿瘤治疗的全新阶段。据介绍，康方生物目前在推动ADC技术的不断发展完善，从靶点、抗体、毒素、连接子和偶联方式五大要素出发，以定点偶联技术、新毒素改造、新连接子为重点探索方向，平衡不同技术关键点，实现整体的毒性控制的同时，提高肿瘤杀伤性，从而实现提高药物治疗窗口、优化疗效和安全性的平衡。目前，康方的双抗ADC已经在全球进行临床研究，初步疗效喜人，IO双抗+双抗ADC疗法即将进入临床。夏瑜指出，创新药研发需坚守长期主义。当前中国创新药已从模仿跟随迈入全球创新行列，在双抗、ADC等领域形成领先优势，但仍需聚焦未被满足的临床需求。康方生物将持续深耕肿瘤治疗领域，同时拓展多疾病赛道，推动中国生物医药产业从“跟跑”向“领跑”跨越。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2587759313","isCrawlerRequest":true}